Dignitana AB (publ) (DIGN.ST)
SEK 0.92
(-2.65%)
SEK 0.92
(-2.65%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 19.1 Million SEK | 4.58% |
| 2022 | 18.26 Million SEK | -22.56% |
| 2021 | 23.59 Million SEK | 144.99% |
| 2020 | 9.62 Million SEK | 29.72% |
| 2019 | 7.42 Million SEK | -27.14% |
| 2018 | 10.18 Million SEK | -35.83% |
| 2017 | 15.87 Million SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 11.21 Million SEK | -41.31% |
| 2024 Q2 | 15.24 Million SEK | 35.97% |
| 2023 Q1 | 9.69 Million SEK | -46.92% |
| 2023 Q3 | 11.72 Million SEK | 1.84% |
| 2023 FY | 19.1 Million SEK | 4.58% |
| 2023 Q4 | 19.1 Million SEK | 62.89% |
| 2023 Q2 | 11.51 Million SEK | 18.77% |
| 2022 Q2 | 9.1 Million SEK | -59.48% |
| 2022 FY | 18.26 Million SEK | -22.56% |
| 2022 Q4 | 18.26 Million SEK | 80.92% |
| 2022 Q1 | 22.46 Million SEK | -4.76% |
| 2022 Q3 | 10.09 Million SEK | 10.9% |
| 2021 Q3 | 4.7 Million SEK | 5.25% |
| 2021 FY | 23.59 Million SEK | 144.99% |
| 2021 Q1 | 7.49 Million SEK | -22.18% |
| 2021 Q2 | 4.47 Million SEK | -40.3% |
| 2021 Q4 | 23.59 Million SEK | 401.06% |
| 2020 Q3 | 9.48 Million SEK | -10.74% |
| 2020 Q4 | 9.62 Million SEK | 1.51% |
| 2020 Q2 | 10.62 Million SEK | 14.45% |
| 2020 Q1 | 9.28 Million SEK | 25.1% |
| 2020 FY | 9.62 Million SEK | 29.72% |
| 2019 Q3 | 10.61 Million SEK | 66.97% |
| 2019 FY | 7.42 Million SEK | -27.14% |
| 2019 Q1 | 9.36 Million SEK | -8.08% |
| 2019 Q2 | 6.35 Million SEK | -32.14% |
| 2019 Q4 | 7.42 Million SEK | -30.05% |
| 2018 Q4 | 10.18 Million SEK | 15.01% |
| 2018 FY | 10.18 Million SEK | -35.83% |
| 2018 Q3 | 8.85 Million SEK | 91.79% |
| 2018 Q2 | 4.61 Million SEK | -8.06% |
| 2018 Q1 | 5.02 Million SEK | -68.36% |
| 2017 Q3 | 11.42 Million SEK | 128.6% |
| 2017 Q2 | 5 Million SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | 15.87 Million SEK | 0.0% |
| 2017 Q4 | 15.87 Million SEK | 38.91% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | -100.0% |
| 2010 Q3 | 4.5 Million SEK | 28.57% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q1 | 3.5 Million SEK | 0.0% |
| 2010 Q2 | 3.5 Million SEK | 0.0% |
| 2009 Q3 | 3.5 Million SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2009 Q2 | 3.5 Million SEK | 0.0% |
| 2009 Q4 | 3.5 Million SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.816% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 98.816% |
| Arcoma AB | 3.87 Million SEK | -393.261% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 91.804% |
| BICO Group AB (publ) | 1.85 Billion SEK | 98.969% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 88.498% |
| CellaVision AB (publ) | 64.7 Million SEK | 70.474% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -4107.93% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | -961.333% |
| Duearity AB (publ) | 10.58 Million SEK | -80.533% |
| Episurf Medical AB (publ) | 5.2 Million SEK | -267.385% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.763% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | -131.574% |
| Iconovo AB (publ) | 7.72 Million SEK | -147.304% |
| Integrum AB (publ) | 6.42 Million SEK | -197.376% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -9172.706% |
| Mentice AB (publ) | 9.55 Million SEK | -99.895% |
| OssDsign AB (publ) | 3.15 Million SEK | -506.476% |
| Paxman AB (publ) | 13.57 Million SEK | -40.781% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 7.848% |
| SciBase Holding AB (publ) | 6.79 Million SEK | -181.065% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 39.902% |
| Sedana Medical AB (publ) | 4.3 Million SEK | -343.66% |
| Senzime AB (publ) | 11.46 Million SEK | -66.585% |
| SpectraCure AB (publ) | 6.71 Million SEK | -184.413% |
| Stille AB | 62.94 Million SEK | 69.648% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.085% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 39.231% |